EN DE

Leveljump Healthcare Corp (JUMP) Fair Value & Analysis

Healthcare · CA · Market cap C$5.3M

LH Leveljump Healthcare Corp JUMP · V
PriceC$0.0550
Fair ValueC$0.1348
Upside+145.1%
Quality43/100
Watch Leveljump Healthcare Corp for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Solidly profitable · 10.3% net margin
Moderate debt · generates free cash flow
Ranks above peers (10/13)
Moderate moat 54/100
Evidence: High Range C$0.1073 – C$0.1788 Share as image

Fair value as of: Aug 13, 2026

From 21 valuation models · updated yesterday

Below-average quality, screening 145% undervalued on our models.

What matters now

  • The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain.
  • The price is below even our cautious bear case (C$0.1073). The market is more pessimistic than our downside scenario.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

C$0.4100 C$0.0450 Fair Value C$0.1348 Apr 2021 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range C$0.0450 – C$0.4100 · fair‑value band C$0.1073 – C$0.1788 · the C$0.0550 price screens below the C$0.1348 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Leveljump Healthcare Corp (JUMP) currently trades at C$0.0550, while our model-based Fair Value estimate is C$0.1348, implying the stock looks roughly 145.1% undervalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Leveljump Healthcare Corp generated revenue of C$18.9M at a net margin of 10.3%. Revenue grew 8.7% year over year. It earns a return on equity of 36.9%. Net debt stands at C$7.4M. Fundamentals as of Aug 13, 2026

Our scenario range runs from C$0.1073 (bear case) to C$0.1788 (bull case); at C$0.0550, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at 145%, JUMP screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF C$0.0100 C$0.0600 C$0.1300 80
Rev-Margin DCF C$0.0200 C$0.0800 C$0.2000 74
Growth-Adj P/E C$0.3900 C$0.5600 C$0.7300 68
All 21 models by family
DCF Models
FCF DCF C$0.0200 C$0.0500 C$0.1500 38
Owner Earnings C$0.1300 C$0.3100 C$0.6300 31
5Y Revenue Exit C$0.0100 C$0.0600 C$0.1600 39
5Y EBITDA Exit C$0.0700 C$0.1800 C$0.3900 41
5Y P/E Exit C$0.1000 C$0.3100 C$0.6000 38
10Y Revenue Exit C$0.0100 C$0.0900 C$0.1300 36
10Y EBITDA Exit C$0.0500 C$0.2000 C$0.4500 37
10Y P/E Exit C$0.0700 C$0.2400 C$0.5400 35
Earnings-Based
Graham-Dodd C$0.0800 C$0.5700 C$0.8000 54
Lynch FV C$0.2900 C$0.4200 C$0.5500 50
PEG = 1.0 C$0.2900 C$0.4200 C$0.5500 46
Multiples
P/E Multiple C$0.2000 C$0.2600 C$0.3300 63
P/S Multiple C$0.1500 C$0.2000 C$0.2600 58
P/B Multiple C$0.1500 C$0.2000 C$0.2600 55
EV/EBITDA C$0.1000 C$0.1500 C$0.2000 54
EV/Revenue C$0.0300 C$0.0500 43
Asset-Based
NCAV (Graham) C$0.0300 C$0.0400 C$0.0700 50
Growth DCF
Growth DCF C$0.0100 C$0.0600 C$0.1300 80
Rev-Margin DCF C$0.0200 C$0.0800 C$0.2000 74
Economic Profit
Residual Income C$0.0600 C$0.0800 C$0.2000 61
Growth Earnings
Growth-Adj P/E C$0.3900 C$0.5600 C$0.7300 68

Widest divergence: Growth Earnings (C$0.5600) versus Asset-Based (C$0.0400). Highest evidence: Growth DCF (80).

Notify me when JUMP reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) C$18.9M
Revenue growth (YoY) +8.7%
Net margin 10.3%
Return on equity 36.9%
Free cash flow C$656K FY2024
P/E ratio 2.8
More key figures
Operating margin 5.5%
EPS (TTM) C$0.0200
Net debt C$7.4M FY2024

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 43/100

Of which business quality 41 · Market factors (momentum, volatility) 30

Profitability 47
Margins and returns on capital today
Quality Growth 86
Are margins and returns improving?
Cashflow 35
Earnings quality: real cash, not paper profit
Fin. Strength 20
Balance sheet, leverage, solvency risk
Investment 26
Disciplined investing over empire-building
Low Volatility 12
Calm price path (market factor)
Momentum 38
Price trend over the last 3–12 months (market factor)
52W Momentum 37
Distance to the 52-week high (market factor)
Net Issuance 40
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Leveljump Healthcare Corp., together with its subsidiaries, provides radiology services. The company offers direct patient images and teleradiology services; in-patient diagnostic imaging facilities, including x-rays, ultrasounds, and mammography; and other medical services. It serves hospitals and clinics. Leveljump Healthcare Corp.

Full company description

Leveljump Healthcare Corp., together with its subsidiaries, provides radiology services. The company offers direct patient images and teleradiology services; in-patient diagnostic imaging facilities, including x-rays, ultrasounds, and mammography; and other medical services. It serves hospitals and clinics. Leveljump Healthcare Corp. is headquartered in Toronto, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Leveljump Healthcare Corp reported revenue of C$17.7M in FY2024 versus C$5.5M in FY2020, a compound +34.3%/yr. Reported net income was C$1.2M in FY2024.

Growth Quality 87/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2024)
C$17.7M
Latest YoY
+40.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+38.2%
Revenue +34.3%/yr
FY20 C$5.5M
FY21 C$6.7M
FY22 C$9.2M
FY23 C$12.6M
FY24 C$17.7M
Net income
FY20 −C$129K
FY21 −C$2.2M
FY22 C$185K
FY23 −C$2.2M
FY24 C$1.2M

Watch JUMP: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Leveljump Healthcare Corp Fair Value". https://www.fairvalue-calculator.com/stock/JUMP

Peer Group

Diagnostics & Research · 136 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 43 · Below median
Fair Value upside +136% · Top 25%
Return on equity (TTM) 37% · Top 25%
Return on assets 2% · Above median
Net margin (TTM) 10% · Above median
Operating margin (TTM) 5% · Below median
Revenue growth 9% · Above median
Debt / equity 0.93× · Higher than 75% of peers

Valuation Multiples vs Diagnostics & Research median · lower = cheaper

P/E (TTM) 2.8× · Cheaper than 75% of peers
P/B 0.60× · Cheaper than 75% of peers
P/S (TTM) 0.20× · Cheaper than 75% of peers
P/FCF 5.8× · Cheaper than median
EV/EBITDA 10.2× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 0
FUTURE 44 · sector 27
PAST 100 · sector 11
HEALTH 54 · sector 96
DIVIDEND 0 · sector 23

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $603.01 $308.19 -49%
Danaher Corporation DHR $205.79 $103.88 -50%
WuXi AppTec Co 2359 HK$198.90 HK$157.39 -21%
Lonza Group LONN CHF 566.20 CHF 259.80 -54%
IDEXX Laboratories, Inc IDXX $570.58 $255.77 -55%
Agilent Technologies, Inc A $148.24 $61.53 -58%
Waters Corporation WAT $416.15 $121.96 -71%
IQVIA Holdings IQV $243.84 $132.17 -46%
Illumina, Inc ILMN $192.91 $95.51 -50%
Mettler-Toledo International Inc MTD $1,437 $615.78 -57%

Compare Leveljump Healthcare Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Leveljump Healthcare Corp (JUMP) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of C$0.1348 versus a price of C$0.0550, about +145% (undervalued).
What is the fair value of JUMP?
Our model-based fair value for Leveljump Healthcare Corp is C$0.1348 (as of Aug 13, 2026), built from audited fundamentals. The current price is C$0.0550.
What is the quality score of JUMP?
Leveljump Healthcare Corp has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Leveljump Healthcare Corp (JUMP)?
Leveljump Healthcare Corp reported trailing-twelve-month revenue of about C$18.9M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of JUMP?
The net profit margin of Leveljump Healthcare Corp is about 10.3%, meaning it keeps roughly 10.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Leveljump Healthcare Corp and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.